2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html